Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
about
Targeted therapies for gastric cancer: current status.Refining docetaxel-containing therapy for gastric cancer.Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
P2860
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Irinotecan, docetaxel and oxal ...... ageal junction adenocarcinoma.
@ast
Irinotecan, docetaxel and oxal ...... ageal junction adenocarcinoma.
@en
type
label
Irinotecan, docetaxel and oxal ...... ageal junction adenocarcinoma.
@ast
Irinotecan, docetaxel and oxal ...... ageal junction adenocarcinoma.
@en
prefLabel
Irinotecan, docetaxel and oxal ...... ageal junction adenocarcinoma.
@ast
Irinotecan, docetaxel and oxal ...... ageal junction adenocarcinoma.
@en
P2093
P2860
P356
P1476
Irinotecan, docetaxel and oxal ...... ageal junction adenocarcinoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603917
P407
P577
2007-07-31T00:00:00Z